Figure 6.
Dose dependent effects of canakinumab at 4 months for CRP, IL-6, and fibrinogen among 556 diabetic patients at high risk for vascular disease. Adapted from Circulation 2012;116:2739-48.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.